A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms.
We have conducted a DNA immunization study to evaluate how the immune response is influenced by the physical structure and secretion of the expressed Ag. For this purpose, we used a series of plasmid constructs encoding different forms of the envelope glycoprotein E of the flavivirus tick-borne encephalitis virus. These included a secreted recombinant subviral particle, a secreted carboxyl-terminally truncated soluble homodimer, a nonsecreted full-length form, and an inefficiently secreted truncated form. Mice were immunized using both i.m. injection and Gene Gun-mediated application of plasmids. The functional immune response was evaluated by determining specific neutralizing and hemagglutination-inhibiting Ab activities and by challenging the mice with a lethal dose of the virus. As a measure for the induction of a Th1 and/or Th2 response, we determined specific IgG subclasses and examined IFN-gamma, Il-4, and Il-5 induction. The plasmid construct encoding a secreted subviral particle, which carries multiple copies of the protective Ag on its surface, was superior to the other constructs in terms of extent and functionality of the Ab response as well as protection against virus challenge. As expected, the type of Th response was largely dependent on the mode of application (i.m. vs Gene Gun), but our data show that it was also strongly influenced by the properties of the Ag. Most significantly, the plasmid encoding the particulate form was able to partially overcome the Th2 bias imposed by the Gene Gun, resulting in a balanced Th1/Th2 response.
Aberle
J H
JH
Institute of Virology, University of Vienna, Austria.
Aberle
S W
SW
Allison
S L
SL
Stiasny
K
K
Ecker
M
M
Mandl
C W
CW
Berger
R
R
Heinz
F X
FX
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D019470:Biolistics; D004669:Encephalitis Viruses, Tick-Borne / Q000235:genetics / Q000276:immunology*; D005260:Female; D007132:Immunoglobulin Isotypes / Q000096:biosynthesis; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D018448:Models, Immunological; D010957:Plasmids / Q000008:administration & dosage / Q000138:chemical synthesis / Q000276:immunology*; D020033:Protein Isoforms / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000138:chemical synthesis / Q000235:genetics / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000138:chemical synthesis / Q000235:genetics* / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000138:chemical synthesis / Q000235:genetics* / Q000276:immunology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007132:Immunoglobulin Isotypes; D020033:Protein Isoforms; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C065696:glycoprotein E, Flavivirus